Table 4.
Polymorphisms of matrix metalloproteinases in hepatocellular carcinoma
| Gene | SNP | Reference | Ethnicity | Case/control | Parameter | Results | Parameter OR | OR | 95% CI | P value |
| MMP-1 | -1607 1G/2G | Zhai[80] | Chinese | 434/480 | Cancer risk | No difference in cancer risk | ||||
| Okamoto[78] | Japanese | 95/83 | Cancer risk | Increased risk of HCC in 2G/2G | 0.002 | |||||
| Clinicopath. par. | No correlation with any clinicopath. par. | |||||||||
| Survival | No difference in survival | |||||||||
| Okamoto[79] | Japanese | 92/170 | Cancer risk | No difference in cancer risk | ||||||
| Survival/clinicopath. par. | No difference in survival/clinicopath. par. | |||||||||
| MMP-2 | -735 C/T | Zhai[80] | Chinese | 434/480 | Cancer risk | No difference in cancer risk | ||||
| Cancer risk | No difference in cancer risk | |||||||||
| MMP-2 | -1306 C/T | Zhai[80] | Chinese | 434/480 | Cancer risk | No difference in cancer risk | ||||
| Wu[82] | Chinese | 93/0 | HCC recurrence after LTx | More CC in recurrence group | CT vs CC | 0.42 | 0.18-0.99 | < 0.05 | ||
| MMP-3 | -1171 5A/6A | Zhai[80] | Chinese | 434/480 | Cancer risk | No difference in cancer risk | ||||
| Okamoto[78] | Japanese | 95/83 | Cancer risk | No difference in cancer risk | ||||||
| HCC diameter at diagnosis | Larger diameter in 5A allele carriers | |||||||||
| Survival | Decreased survival in 5A allele carriers | |||||||||
| Okamoto[79] | Japanese | 92/170 | Cancer risk | Increased cancer risk in 5A allele carriers | ||||||
| Survival/clinicopath. par. | Decreased survival in 5A allele carriers | 0.035 | ||||||||
| MMP-7 | -181 A/G | Qiu[81] | Chinese | 434/480 | Cancer risk | No difference in cancer risk | ||||
| MMP-8 | -799 C/T | Qiu[81] | Chinese | 434/480 | Cancer risk | No difference in cancer risk | ||||
| MMP-9 | -1562 C/T | Zhai[80] | Chinese | 434/480 | Cancer risk | No difference in cancer risk | ||||
| Wu[82] | Chinese | 93/0 | HCC recurrence after LTx | No difference in HCC recurrence | ||||||
| Okamoto[78] | Japanese | 95/83 | Cancer risk | No difference in cancer risk | ||||||
| Differentiation grade | Differentiation worse in T allele carriers | 0.03 | ||||||||
| Survival | No difference in survival | |||||||||
| Okamoto[79] | Japanese | 92/170 | Cancer risk | No difference in cancer risk | ||||||
| Survival/clinicopath. par. | No difference in survival/clinicopath. par. | |||||||||
| MMP-12 | -82 A/G | Zhai[80] | Chinese | 434/480 | Cancer risk | No difference in cancer risk | ||||
| MMP-13 | -77 A/G | Zhai[80] | Chinese | 434/480 | Cancer risk | No difference in cancer risk | ||||
| MMP-21 | C572T | Qiu[81] | Chinese | 434/480 | Cancer risk | No difference in cancer risk | ||||
| TIMP-2 | -418 G/C | Okamoto[83] | Japanese | 92/70 | Cancer risk HCC | No difference in cancer risk | ||||
| Survival | No difference in survival |
SNP: Single nucleotide polymorphism; LN: Lymph node; Clinicopath. par.: Clinicopathological parameters; OR: Odds ratio; 95% CI: 95% confidence interval; HCC: Hepatocellular carcinoma; LTx: Liver transplantation.